Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | +15.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.37 | N/A | +15.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over market conditions impacting performance. They reiterated their commitment to long-term goals.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.
Nektar Therapeutics reported a wider-than-expected loss per share, which surprised investors positively, but the lack of revenue data and guidance contributed to a stock decline of 1.35%. The management's cautious tone suggests ongoing challenges, which may weigh on investor sentiment moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UNUM GROUP
Aug 5, 2013